The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...
Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...
The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...
The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...
This was the stock's third consecutive day of losses.
Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...
Bristol Myers Squibb CEO Christopher Boerner joins 'Mad Money' host Jim Cramer to talk its new schizophrenia treatment ...
Zacks.com on MSN7h
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key FactsThe latest trading day saw Bristol Myers Squibb (BMY) settling at $56.29, representing a -0.16% change from its previous close.
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
The stock's rise snapped a three-day losing streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback